REGISTER
NMPA Approves AbbVie's Epcoritamab Plus Rituximab and Lenalidomide for Relapsed/Refracto
China's NMPA has approved epcoritamab (Epkinly) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL). This marks epcoritamab's first approval in China.

On May 15, China's National Medical Products Administration (NMPA) approved epcoritamab (trade name: Epkinly), developed by AbbVie, in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL) (application number: JXSS2500127/8). The application had previously been granted priority review.

Epcoritamab was originally developed by Genmab. In 2020, AbbVie entered into a collaboration with Genmab totaling USD 3.9 billion to co-develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab.

As an IgG1 bispecific antibody, epcoritamab simultaneously binds CD3 on T cells and CD20 on B cells, triggering T cell-mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

Epcoritamab received its first global approval in May 2023. To date, it has been approved in the United States, the European Union, Japan, and other markets for large B-cell lymphoma and follicular lymphoma. In 2025, global sales of epcoritamab reached USD 468 million. This NMPA approval represents epcoritamab's first authorization in China.

The pivotal Phase III EPCORE FL-1 trial (CTR20230864/CTR20234072) evaluated epcoritamab plus rituximab and lenalidomide (R2) versus rituximab and lenalidomide alone in patients with relapsed/refractory FL. The dual primary endpoints were overall response rate (ORR) and progression-free survival (PFS). Data from this study were presented at the 2025 ASH Annual Meeting.

Results showed that epcoritamab plus R2 reduced the risk of disease progression or death by 79% compared with R2 alone (HR 0.21, p<0.0001). The ORR in the epcoritamab plus R2 arm was 95%, compared with 79% in the R2 arm.

In addition to EPCORE FL-1, AbbVie is conducting four additional Phase III clinical trials of epcoritamab in China:

• Epcoritamab versus investigator-choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (CTR20221558)

• Epcoritamab plus R-CHOP for newly diagnosed DLBCL (CTR20231626/CTR20231627)

• Epcoritamab plus rituximab and lenalidomide (R2) for previously untreated FL (CTR20243120)

• Epcoritamab plus oral lenalidomide for relapsed/refractory DLBCL (CTR20244540/CTR20244542)

CD20×CD3 bispecific antibodies represent one of the most active drug classes in hematologic oncology. According to the Insight database, four CD20×CD3 bispecific antibodies have received global approval: mosunetuzumab (Roche/Biogen), glofitamab (Roche), epcoritamab (AbbVie/Genmab), and odronextamab (Regeneron/Zymeworks). In China, three of the four are now approved; odronextamab remains in Phase II clinical development. More than ten additional CD20×CD3 bispecific antibodies are in clinical stages in China, from developers including CSPC Pharmaceutical Group (Phase III), Sinocelltech (Phase III), Junshi Biosciences (Phase II), and Kineta (Phase I/II).

0
0
Loading